Nwam LLC Reduces Holdings in Pfizer Inc. (NYSE:PFE)

Nwam LLC reduced its stake in Pfizer Inc. (NYSE:PFE) by 7.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 50,415 shares of the biopharmaceutical company’s stock after selling 3,921 shares during the period. Nwam LLC’s holdings in Pfizer were worth $1,338,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PFE. Retirement Wealth Solutions LLC purchased a new stake in Pfizer during the 4th quarter valued at $26,000. Gladius Capital Management LP boosted its holdings in shares of Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 38,015 shares during the period. Sierra Ocean LLC bought a new position in Pfizer during the 4th quarter valued at approximately $34,000. Teachers Insurance & Annuity Association of America purchased a new stake in Pfizer in the 3rd quarter worth approximately $35,000. Finally, Joseph Group Capital Management grew its position in shares of Pfizer by 168.3% in the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 771 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the subject of a number of recent analyst reports. Bank of America restated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. UBS Group decreased their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Citigroup cut their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Guggenheim reissued a “buy” rating and issued a $33.00 price target on shares of Pfizer in a research note on Monday, February 10th. Finally, Truist Financial cut their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Stock Performance

PFE stock opened at $26.09 on Friday. The stock has a market capitalization of $147.83 billion, a PE ratio of 18.50, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The stock’s 50 day simple moving average is $26.35 and its 200 day simple moving average is $27.35. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same period last year, the firm posted $0.10 earnings per share. Pfizer’s revenue was up 24.7% compared to the same quarter last year. As a group, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.59%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s payout ratio is presently 121.99%.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.06% of the stock is owned by insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.